Adam Schmitt

Dr. Adam Schmitt


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Cancer Cell
Verified
Journal Article
Closed access
ASAdam Schmitt
Adam Schmitt
HCHoward Y. Chang
Howard Y. Chang

26 September 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ASAdam Schmitt
Adam Schmitt
JGJulia T Garcia
Julia T Garcia
THTiffany Hung
Tiffany Hung
RFRyan A Flynn
Ryan A Flynn
YSYing Shen
Ying Shen
HCHoward Y Chang
Howard Y Chang
Howard Chang and colleagues identify a long noncoding RNA, DINO, that is transcribed upstream of CDKN1A and induced by p53 in response to DNA damage. They show that DINO binds to p53 protein and promotes its stabilization, producing a feedback loop that amplifies DNA damage signaling. Long noncoding RNAs (lncRNAs) are prevalent genes with frequently precise regulation but mostly unknown functions. Here we demonstrate that lncRNAs guide the organismal DNA damage response. DNA damage activated transcription of the DINO (Damage Induced Noncoding) lncRNA via p53. DINO was required for p53-dependent gene expression, cell cycle arrest and apoptosis in response to DNA damage, and DINO expression was sufficient to activate damage signaling and cell cycle arrest in the absence of DNA damage. DINO bound to p53 protein and promoted its stabilization, mediating a p53 auto-amplification loop. Dino knockout or promoter inactivation in mice dampened p53 signaling and ameliorated acute radiation syndrome in vivo. Thus, inducible lncRNA can create a feedback loop with its cognate transcription factor to amplify cellular signaling networks.

13 February 2017 in Cold Spring Harbor Perspectives in Medicine
Verified
Journal Article
Open access
PDF file
ASAdam Schmitt
Adam Schmitt
HCHoward Y. Chang
Howard Y. Chang
Although only 2% of the genome encodes protein, RNA is transcribed from the majority of the genetic sequence, suggesting a massive degree of cellular functionality is programmed in the noncoding genome. The mammalian genome contains tens of thousands of long noncoding RNAs (lncRNAs), many of which occur at disease-associated loci or are specifically expressed in cancer. Although the vast majority of lncRNAs have no known function, recurring molecular mechanisms for lncRNAs are now being observed in chromatin regulation and cancer pathways and emerging technologies are now providing tools to interrogate lncRNA molecular interactions and determine function of these abundant cellular macromolecules.

1 December 2011 in Molecular Cell
Verified
Journal Article
Closed access
ASAdam Schmitt
Adam Schmitt
CCClayton D. Crawley
Clayton D. Crawley
SKShijune Kang
Shijune Kang
DRDavid R. Raleigh
David R. Raleigh
XYXiaohong Yu
Xiaohong Yu
BYBakhtiar Yamini
Bakhtiar Yamini

14 August 2013 in Nature
Verified
Journal Article
Open access
PDF file
ASAdam Schmitt
Adam Schmitt
HCHoward Y. Chang
Howard Y. Chang
The discovery of long non-coding RNAs that control the liaisons between a transcription factor with a key role in prostate cancer and its target genes sheds light on how RNAs dictate information flow in the cell nucleus. See Letter p.598 Several long non-coding RNAs (lncRNAs) are known to be overexpressed in prostate cancer. Michael Rosenfeld and colleagues have investigated the mechanistic and biological roles of two of these, known as PRNCR1 and PCGEM1. Both are found to interact with the androgen receptor (AR) dependent on specific post-translational modifications, and to enhance the looping of AR-bound enhancers to target gene promoters, leading to enhanced gene expression. They also enhance AR-mediated proliferation in prostate cancer cells and are required for tumour growth in a prostate cancer xenograft mouse model. PRNCR1 and PCGEM1 are upregulated in castration-resistant prostate cancer cell lines. The regulatory roles of lncRNAs in prostate cancer uncovered in this manuscript may open the way to new therapeutic approaches.

1 January 2017 in Neurosurgical Focus
Verified
Journal Article
Closed access
DLDennis T. Lockney
Dennis T. Lockney
TSTimothy Shub
Timothy Shub
BHBenjamin Hopkins
Benjamin Hopkins
NLNatalie A. Lockney
Natalie A. Lockney
NMNelson Moussazadeh
Nelson Moussazadeh
MBMark H Harvey Bilsky
Mark H Harvey Bilsky
OBJECTIVE: Chordoma is a rare malignant tumor for which en bloc resection with wide margins is advocated as primary treatment. Unfortunately, due to anatomical constraints, en bloc resection to achieve wide or marginal margins is not feasible for many patients as the resulting morbidity would be prohibitive. The objective of this study was to evaluate the efficacy of intralesional curettage and separation surgery followed by spinal stereotactic body radiation therapy (SBRT) in patients with chordomas in the mobile spine. METHODS: The authors performed a retrospective chart review of all patients with chordoma in the mobile spine treated from 2004 to 2016. Patients were identified from a prospectively collected database. Initially 22 patients were identified with mobile spine chordomas. With inclusion criteria of cytoreductive separation surgery followed closely by SBRT and a minimum of 6 months of follow-up imaging, 12 patients were included. Clinical and pathological characteristics of each patient were collected and data were analyzed. Patients were divided into two cohorts—those undergoing intralesional resection followed by SBRT as initial chordoma treatment at Memorial Sloan Kettering Cancer Center (MSKCC) (Cohort 1) and those undergoing salvage treatment following recurrence (Cohort 2). Treatment toxicities were classified according to the Common Terminology Criteria for Adverse Events version 4.03. Overall survival was analyzed using Kaplan-Meier analysis. RESULTS: The 12 patients had a median post-SBRT follow-up time of 26 months. Cohort 1 had 5 patients with median post-SBRT follow-up time of 65.9 months and local control rate of 80% at last follow-up. Only one patient had disease progression, at 48.2 months following surgery and SBRT. Cohort 2 had 7 patients who had been treated at other institutions prior to undergoing both surgery and SBRT (salvage therapy) at MSKCC. The local control rate was 57.1% and the median follow-up duration was 10.7 months. One patient required repeat irradiation. Major surgery- and radiation-related complications occurred in 18% and 27% of patients, respectively. Epidural spinal cord compression scores were collected for each patient pre- and postoperatively. CONCLUSIONS: The combination of surgery and SBRT provides excellent local control following intralesional curettage and separation surgery for chordomas in the mobile spine. Patients who underwent intralesional curettage and spinal SBRT as initial treatment had better disease control than those undergoing salvage therapy. High-dose radiotherapy may offer several biological benefits for tumor control.